LOUISVILLE, Ky. & VISTA, Calif.--(BUSINESS WIRE)--PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.
“The automation provided by the AutoGenomics’ INFINITI® Analyzer will enhance workflow in our laboratories,” said Mark Linder, Executive Vice-President of Operations and Co-Founder of PGXL Laboratories. He further stated that “with their comprehensive menu of molecular applications in the pharmacogenetics arena, we have found AutoGenomics to be a very suitable partner in meeting our emerging testing needs.”
“We are excited to partner with PGXL Labs who have pioneered in bringing the benefits of pharmacogenetics testing to patients across the country,” said Ramanath Vairavan, Senior Vice President of AutoGenomics. “The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests.”
PGXL plans to utilize the INFINITI® Warfarin Assay and the CYP450 2C19 assay, both of which have been cleared by the FDA. In addition, they will plan to use the INFINITI® KRAS-BRAF test.
About PGXL Laboratories
A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It provides pharmacogenetic testing and interpretive services, and developed one of the first commercial CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers of pharmaceuticals and medical equipment. www.pgxlab.com
About AutoGenomics
AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray-based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com